Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros










Base de datos
Tipo de estudio
Intervalo de año de publicación
1.
Cell Death Dis ; 12(12): 1105, 2021 11 26.
Artículo en Inglés | MEDLINE | ID: mdl-34824192

RESUMEN

Systemic hypoxia is a common element in most perinatal emergencies and is a known driver of Bnip3 expression in the neonatal heart. Bnip3 plays a prominent role in the evolution of necrotic cell death, disrupting ER calcium homeostasis and initiating mitochondrial permeability transition (MPT). Emerging evidence suggests a cardioprotective role for the prostaglandin E1 analog misoprostol during periods of hypoxia, but the mechanisms for this protection are not completely understood. Using a combination of mouse and cell models, we tested if misoprostol is cardioprotective during neonatal hypoxic injury by altering Bnip3 function. Here we report that hypoxia elicits mitochondrial-fragmentation, MPT, reduced ejection fraction, and evidence of necroinflammation, which were abrogated with misoprostol treatment or Bnip3 knockout. Through molecular studies we show that misoprostol leads to PKA-dependent Bnip3 phosphorylation at threonine-181, and subsequent redistribution of Bnip3 from mitochondrial Opa1 and the ER through an interaction with 14-3-3 proteins. Taken together, our results demonstrate a role for Bnip3 phosphorylation in the regulation of cardiomyocyte contractile/metabolic dysfunction, and necroinflammation. Furthermore, we identify a potential pharmacological mechanism to prevent neonatal hypoxic injury.


Asunto(s)
Proteínas 14-3-3/metabolismo , Cardiopatías/tratamiento farmacológico , Proteínas de la Membrana/metabolismo , Misoprostol/uso terapéutico , Proteínas Mitocondriales/metabolismo , Oxitócicos/uso terapéutico , Animales , Modelos Animales de Enfermedad , Humanos , Misoprostol/farmacología , Oxitócicos/farmacología , Ratas , Transfección
2.
Ann Surg ; 269(5): 979-987, 2019 05.
Artículo en Inglés | MEDLINE | ID: mdl-29135495

RESUMEN

OBJECTIVE: We aimed to evaluate the use of miR-200b as a prenatal transplacental therapy in the nitrofen rat model of abnormal lung development and congenital diaphragmatic hernia (CDH). BACKGROUND: Pulmonary hypoplasia (PH) and pulmonary hypertension determine mortality and morbidity in CDH babies. There is no safe medical prenatal treatment available. We previously discovered that higher miR-200b is associated with better survival in CDH babies. Here, we investigate the role of miR-200b in the nitrofen rat model of PH and CDH and evaluate its use as an in vivo prenatal therapy. METHODS: We profiled miR-200b expression during nitrofen-induced PH using RT-qPCR and in situ hybridization in the nitrofen rat model of PH and CDH. The effects of nitrofen on downstream miR-200b targets were studied in bronchial lung epithelial cells using a SMAD luciferase assay, Western blotting and Immunohistochemistry. We evaluated miR-200b as a lung growth promoting therapy ex vivo and in vivo using lung explant culture and transplacental prenatal therapy in the nitrofen rat model. RESULTS: We show that late lung hypoplasia in CDH is associated with (compensatory) upregulation of miR-200b in less hypoplastic lungs. Increasing miR-200b abundance with mimics early after nitrofen treatment decreases SMAD-driven TGF-ß signaling and rescues lung hypoplasia both in vitro and in vivo. Also, prenatal miR-200b therapy decreases the observed incidence of CDH. CONCLUSIONS: Our data indicate that miR-200b improves PH and decreases the incidence of CDH. Future studies will further exploit this newly discovered prenatal therapy for lung hypoplasia and CDH.


Asunto(s)
Anomalías Múltiples/terapia , Terapias Fetales/métodos , Hernias Diafragmáticas Congénitas/terapia , Enfermedades Pulmonares/terapia , Pulmón/anomalías , MicroARNs/uso terapéutico , 2,4-Dinitrofenol/administración & dosificación , Anomalías Múltiples/genética , Animales , Modelos Animales de Enfermedad , Hernias Diafragmáticas Congénitas/inducido químicamente , Hernias Diafragmáticas Congénitas/complicaciones , Hernias Diafragmáticas Congénitas/genética , Enfermedades Pulmonares/complicaciones , Enfermedades Pulmonares/genética , Ratas , Ratas Sprague-Dawley
3.
Sci Rep ; 7(1): 6382, 2017 07 25.
Artículo en Inglés | MEDLINE | ID: mdl-28743913

RESUMEN

miR-200b plays a role in epithelial-to-mesenchymal transition (EMT) in cancer. We recently reported abnormal expression of miR-200b in the context of human pulmonary hypoplasia in congenital diaphragmatic hernia (CDH). Smaller lung size, a lower number of airway generations, and a thicker mesenchyme characterize pulmonary hypoplasia in CDH. The aim of this study was to define the role of miR-200b during lung development. Here we show that miR-200b-/- mice have abnormal lung function due to dysfunctional surfactant, increased fibroblast-like cells and thicker mesenchyme in between the alveolar walls. We profiled the lung transcriptome in miR-200b-/- mice, and, using Gene Ontology analysis, we determined that the most affected biological processes include cell cycle, apoptosis and protein transport. Our results demonstrate that miR-200b regulates distal airway development through maintaining an epithelial cell phenotype. The lung abnormalities observed in miR-200b-/- mice recapitulate lung hypoplasia in CDH.


Asunto(s)
Células Epiteliales/citología , Pulmón/crecimiento & desarrollo , MicroARNs/genética , Regulación hacia Arriba , Animales , Células Epiteliales/patología , Perfilación de la Expresión Génica/métodos , Regulación del Desarrollo de la Expresión Génica , Técnicas de Inactivación de Genes , Ontología de Genes , Redes Reguladoras de Genes , Hernias Diafragmáticas Congénitas/genética , Hernias Diafragmáticas Congénitas/fisiopatología , Humanos , Pulmón/citología , Pulmón/fisiopatología , Ratones , Pruebas de Función Respiratoria , Análisis de Secuencia de ARN
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...